Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial.
A. Lorch
No relevant relationships to disclose
A. Kleinhans
No relevant relationships to disclose
A. Kramar
No relevant relationships to disclose
J. T. Hartmann
No relevant relationships to disclose
C. Bokemeyer
No relevant relationships to disclose
O. Rick
No relevant relationships to disclose
J. Beyer
No relevant relationships to disclose